Chongqing Kerun Biopharmaceutical Research and Development

Chongqing Kerun Biopharmaceutical Research and Development is a Chinese biotechnology company specializing in the research, development, and manufacturing of recombinant protein therapeutics. Founded in 2007, the company utilizes advanced genetic engineering and protein purification platforms to produce biologics for hematology, oncology, and endocrinology. Its commercial portfolio includes recombinant human erythropoietin (rhEPO), granulocyte colony-stimulating factor (rhG-CSF), and interferon α2b. The company is also advancing a pipeline of biosimilars and innovative proteins, including growth hormones and parathyroid hormones. Headquartered in Chongqing, Kerun Biopharmaceutical operates GMP-certified facilities and is recognized as a key player in the regional biopharmaceutical sector.